Liquidia Corporation (NASDAQ:LQDA) is one of the best hot stocks to invest in. On October 9, BofA raised the firm’s price target on Liquidia to $37 from $35 and kept a Buy rating on the shares. BofA previewed Q3 2025 EPS updates for its commercial-stage biopharma coverage and does not expect any major Q3 beats/misses and no big 2026 revisions among the group.
Liquidia reported its Q2 2025 earnings with a strong launch of its product, YUTREPIA (treprostinil inhalation powder). The quarter’s total revenue reached $8.8 million. This was comprised of $6.5 million from YUTREPIA product sales, which began shipping in June, and $2.3 million in service revenue related to a promotion agreement for treprostinil injection with Sandoz.
Commercially, the company has signed contracts with major commercial payers, which is expected to improve market access and remove new-to-market blocks in the coming quarters. However, the initial $6.5 million revenue was attributed primarily to channel inventory, with patient demand expected to drive growth into Q3.
Liquidia Corporation is a biopharmaceutical company that develops, manufactures, and commercializes various products for unmet patient needs in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
